G L Phillips
Overview
Explore the profile of G L Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
1269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Arboli E, Phillips G, Pardee T, Lazarus H, Gale R
Leukemia
. 2025 Mar;
PMID: 40074851
No abstract available.
2.
Gale R, Phillips G, Lazarus H
Leukemia
. 2024 Mar;
38(8):1663-1666.
PMID: 38459165
No abstract available.
3.
Bensinger W, Becker P, Gooley T, Chauncey T, Maloney D, Gopal A, et al.
Bone Marrow Transplant
. 2015 Sep;
51(1):67-71.
PMID: 26367217
We aimed to examine whether doses of melphalan higher than 200 mg/m(2) improve response rates when used as conditioning before autologous transplant (ASCT) in multiple myeloma (MM) patients. Patients with...
4.
Blumberg N, Heal J, Liesveld J, Phillips G, Rowe J
Leukemia
. 2007 Sep;
22(3):631-5.
PMID: 17805333
No abstract available.
5.
Heal J, Liesveld J, Phillips G, Blumberg N
Bone Marrow Transplant
. 2005 Jul;
36(9):747-55.
PMID: 16044140
ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring...
6.
Phillips G, Abboud C, Bernstein S, Friedberg J, Ifthikharuddin J, Lancet J, et al.
Semin Oncol
. 2005 Feb;
31(6 Suppl 18):59-61.
PMID: 15726525
We and others have previously shown that the use of amifostine (Ethyol; MedImmune Inc, Gaithersburg, MD) can ameliorate certain regimen-related toxicities of high-dose melphalan (HD-MEL) in the autologous hematopoietic stem...
7.
Rapoport A, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E, et al.
Bone Marrow Transplant
. 2004 Nov;
34(10):883-90.
PMID: 15517008
Relapse remains a major cause of treatment failure after autotransplantation (auto-PBSCT) for Hodgkin's disease (HD). The administration of non-crossresistant therapies during the post-transplant period may delay or prevent relapse. We...
8.
Phillips G, Meisenberg B, Reece D, Adams V, Badros A, Brunner J, et al.
Biol Blood Marrow Transplant
. 2004 Jun;
10(7):473-83.
PMID: 15205668
This study was conducted to define a new maximum tolerated dose and the dose-limiting toxicity (DLT) of melphalan and autologous hematopoietic stem cell transplantation (AHSCT) when used with the cytoprotective...
9.
Phillips G, Meisenberg B, Reece D, Adams V, Badros A, Brunner J, et al.
Bone Marrow Transplant
. 2004 Feb;
33(8):781-7.
PMID: 14767498
High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma,...
10.
Horan J, Liesveld J, Fernandez I, Lyman G, Phillips G, Lerner N, et al.
Bone Marrow Transplant
. 2003 Jul;
32(3):293-8.
PMID: 12858201
The impact of peripheral blood stem cell transplantation (PBSCT) on survival relative to bone marrow transplantation (BMT) remains poorly defined. Several randomized controlled trials (RCTs) comparing HLA-matched related PBSC- and...